Abstract:BACKGROUND/AIMS: This study is the first randomized prospective clinical trial of interferon in hepatitis to be conducted according to the guidelines of Good Clinical Practice (GCP) in China. The object of this study is to compare the long-term efficacy of a dose of 3MU of recombinant IFN alpha 2a (rIFN-alpha 2a) three times a week (t.i.w.) for 6 months with a starting dose of 6MU for 3 months and subsequent reduction to 3 MU t.i.w for a further 3 months.METHODOLOGY: Sixty-eight serological and histologically proven chronic hepatitis C patients with elevated serum ALT were randomized into two groups. A total of 63 patients were studied with full course of treatment. Five patients were withdrawn from the trial, 2 due to personal reasons and 3 due to adverse drug reactions during treatment. Thirty patients received 6MU IFN-alpha 2a t.i.w. for 3 months followed by 3MU t.i.w. for another 3 months (group A). Thirty-three patients received 3MU IFN-alpha 2a t.i.w. for 6 months (group B).RESULTS: The sex, age, baseline serum bilirubin, ALT and AST levels were matched in both groups. At the end of 6 months the complete and partial response rates in group A were 60.0% and 16.7%, respectively, and the clearance of serum HCV-RNA was 53.3%. In group B, the complete and partial response rates were 72.7% and 3.0%, respectively, and the clearance of HCV-RNA was 61.3%. These patients were followed up for 6, 12, and 18 months after stopping treatment. In group A, the rates of complete normalization of ALT and clearance of serum HCV-RNA at 24 months were 50.0% and 60.0%, respectively. In group B, the rates of normalization of ALT and clearance of HCV-RNA at 24 months were 54.4% and 41.9%, respectively. The efficacy between the two groups showed no statistically significant difference; the response rates of treatment were similar to the patients with HCV genotype 1b and 2a. Six patients (10.8% of the study population) developed neutralization antibodies to IFN-alpha 2a during treatment, 4 of them responded to the treatment. Adverse drug reactions (ADR) were common, but most of them were tolerable and the incidence of ADR was similar in both groups.CONCLUSIONS: IFN-alpha 2a is effective in the treatment of Chinese patients with chronic hepatitis C. The sustained response rates and ADR among two dose schedule groups are similar.

The Survey of the Efficiency of α-2b Interferon Film to Cure 24 Patients with Herps Simples

A Double-blind Randomized Controlled Clinical Trial of Recombinant Interferon α-2a Gel Versus Placebo in Treatment of Herpes Simplex

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Observations on the Efficacy of Acupuncture Point Injection of Interferon in Treating Herpes Zoster

Efficacy and safety of interferon α-2b spray for herpangina in children: A randomized, controlled trial

An Observation on the Effectiveness of the Patient with Chronic Hepatitis C by Combining Interferon and Ribavirin

A Randomized Controlled Multicenter Clinical Trial on Theefficacy and Safety of Recombinant Interferon Α-2A(yeast) Injection in Treatment of Herpes Zoster

Clinical obser ration of interferon α-2b on the treatment of viral keratitis:476 cases study

THE EFFECTIVENESS OF NATIVE RECOMBINANT INTERFERON Α-2B ON 45 CASES OF CHRONIC HEPATITIS C

A Clinical Epidemiological Study on HGV Infection with α-inter-feron Therapy

[A Clinical Study of the Efficacy and Safety of Secretory Human Interferon Alpha-2A Treatment for Chronic Hepatitis B].

HCV Genotype,Serum HCV RNA Load,Liver Lesion and Efficacy of α- Interferon on Patients with Chronic Hepatitis C

Interferon α-2a suppositories in treating cervical erosion in 356 patients

Study of Interferon on Children Respiratory Infection

Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.

Effects of recombinant IFN α-2b suppository on herpes simplex viruses

Long-Term Efficacy of Recombinant Interferon Alpha 2a in the Treatment of Chronic Hepatitis C: A Randomized Prospective Study Comparing Two Dose Schedules in Chinese Patients

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

Clinical Observasion of Interferon in the Retreatment of 32 Patients with Chronic Hepatitis C

Application of Quality of Life Assessment in the Efficacy Evaluation of Interferon in the Treatment of Chronic Hepatitis C

Analysis of Therapeutic Effect in 21 Invasive Fungus Infection(ifi) Patients with Hematopathy